Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 134,986 251,929 319,053 656,089
Total Sell Value $11,097,511 $21,508,551 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 9 19 27 56
End Date 2024-04-07 2024-01-05 2023-07-07 2022-07-07

   
Records found: 1285
  Page 43 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Davis George Eric EVP, General Counsel   •       –      –    2016-04-29 4 A $51.26 $21,223 D/D 414 91,894     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2016-04-29 4 A $51.26 $21,275 D/D 415 63,487     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-04-29 4 A $51.26 $21,223 D/D 414 395,635     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-04-06 4 OE $14.39 $21,585 D/D 1,500 395,221     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-04-05 4 OE $14.39 $21,585 D/D 1,500 393,721     -
   Mueller Brian VP, Corporate Controller   •       –      –    2016-03-16 4 D $80.34 $30,208 D/D (376) 15,247     -
   Mueller Brian VP, Corporate Controller   •       –      –    2016-03-15 4 A $0.00 $0 D/D 3,570 15,623     -
   Davis George Eric EVP, General Counsel   •       –      –    2016-03-15 4 A $0.00 $0 D/D 15,290 91,480     -
   Baffi Robert EVP, Technical Operations   •       –      –    2016-03-15 4 A $0.00 $0 D/D 16,190 138,626     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2016-03-15 4 A $0.00 $0 D/D 16,640 63,933     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-03-15 4 A $0.00 $0 D/D 60,710 392,221     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2016-03-15 4 A $0.00 $0 D/D 19,790 120,666     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2016-03-15 4 A $0.00 $0 D/D 16,190 63,072     -
   Davis George Eric EVP, General Counsel   •       –      –    2016-03-14 4 S $86.21 $172,079 D/D (1,996) 76,190     -
   Baffi Robert EVP, Technical Operations   •       –      –    2016-03-07 4 GA $0.00 $0 I/I 2,191 82,269     -
   Baffi Robert EVP, Technical Operations   •       –      –    2016-03-07 4 GD $0.00 $0 D/D 2,191 69,448     -
   Ajer Jeffrey Robert SVP, Chief Commercial Officer   •       –      –    2016-03-04 4 AS $88.42 $110,970 D/D (1,255) 46,882     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-03-03 4 D $89.57 $805,145 D/D (8,989) 331,511     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2016-03-03 4 D $89.57 $214,520 D/D (2,395) 47,293     -
   Baffi Robert EVP, Technical Operations   •       –      –    2016-03-03 4 D $89.57 $214,520 D/D (2,395) 71,639     -
   Baffi Robert EVP, Technical Operations   •       –      –    2016-03-03 4 GA $0.00 $0 I/I 45,727 80,078     -
   Baffi Robert EVP, Technical Operations   •       –      –    2016-03-03 4 GD $0.00 $0 D/D 45,727 74,034     -
   Ajer Jeffrey Robert SVP, Chief Commercial Officer   •       –      –    2016-03-03 4 D $89.57 $214,520 D/D (2,395) 48,137     -
   Davis George Eric EVP, General Counsel   •       –      –    2016-03-03 4 D $89.57 $195,263 D/D (2,180) 78,186     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2016-03-03 4 D $89.57 $272,562 D/D (3,043) 100,876     -
  1285 Records found
  Previous  40  41  42  43  44  45  46  47  48  49  Next   
  Page 43 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us